BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11361019)

  • 21. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
    Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
    Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Roles of DT diaphorase in the genotoxicity of nitroaromatic compounds in human and fish cell lines.
    Hasspieler BM; Haffner GD; Adeli K
    J Toxicol Environ Health; 1997 Oct; 52(2):137-48. PubMed ID: 9310146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CB 1954: from the Walker tumor to NQO2 and VDEPT.
    Knox RJ; Burke PJ; Chen S; Kerr DJ
    Curr Pharm Des; 2003; 9(26):2091-104. PubMed ID: 14529407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delivery of the bacterial nitroreductase gene into endothelial cells prolongs the survival of tumour-bearing mice by bystander mechanisms.
    Benouchan M; Do Nascimento F; Perret GY; Colombo BM
    Int J Oncol; 2006 Feb; 28(2):457-62. PubMed ID: 16391801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DT-diaphorase: possible roles in cancer chemotherapy and carcinogenesis.
    Rauth AM; Goldberg Z; Misra V
    Oncol Res; 1997; 9(6-7):339-49. PubMed ID: 9406240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under hypoxia.
    Begleiter A; Robotham E; Leith MK
    Mol Pharmacol; 1992 Apr; 41(4):677-82. PubMed ID: 1373799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.
    Green NK; Youngs DJ; Neoptolemos JP; Friedlos F; Knox RJ; Springer CJ; Anlezark GM; Michael NP; Melton RG; Ford MJ; Young LS; Kerr DJ; Searle PF
    Cancer Gene Ther; 1997; 4(4):229-38. PubMed ID: 9253508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
    Taub JW; Huang X; Ge Y; Dutcher JA; Stout ML; Mohammad RM; Ravindranath Y; Matherly LH
    Cancer Res; 2000 Nov; 60(22):6421-6. PubMed ID: 11103808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.
    Friedlos F; Davies L; Scanlon I; Ogilvie LM; Martin J; Stribbling SM; Spooner RA; Niculescu-Duvaz I; Marais R; Springer CJ
    Cancer Res; 2002 Mar; 62(6):1724-9. PubMed ID: 11912146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines.
    Mikami K; Naito M; Tomida A; Yamada M; Sirakusa T; Tsuruo T
    Cancer Res; 1996 Jun; 56(12):2823-6. PubMed ID: 8665520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).
    Knox RJ; Friedlos F; Boland MP
    Cancer Metastasis Rev; 1993 Jun; 12(2):195-212. PubMed ID: 8375021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase.
    Friedlos F; Court S; Ford M; Denny WA; Springer C
    Gene Ther; 1998 Jan; 5(1):105-12. PubMed ID: 9536271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations.
    Jaberipour M; Vass SO; Guise CP; Grove JI; Knox RJ; Hu L; Hyde EI; Searle PF
    Biochem Pharmacol; 2010 Jan; 79(2):102-11. PubMed ID: 19665450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.
    Wolfe LA; Mullin RJ; Laethem R; Blumenkopf TA; Cory M; Miller JF; Keith BR; Humphreys J; Smith GK
    Bioconjug Chem; 1999; 10(1):38-48. PubMed ID: 9893962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of redox cycling and activation by DT-diaphorase in the cytotoxicity of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB-1954) and its analogs.
    Miŝkiniene V; Sergediene E; Nemeikaite A; Segura-Aguilar J; Cenas N
    Cancer Lett; 1999 Nov; 146(2):217-22. PubMed ID: 10656629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR).
    Singleton DC; Li D; Bai SY; Syddall SP; Smaill JB; Shen Y; Denny WA; Wilson WR; Patterson AV
    Cancer Gene Ther; 2007 Dec; 14(12):953-67. PubMed ID: 17975564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures.
    Wilson WR; Pullen SM; Hogg A; Helsby NA; Hicks KO; Denny WA
    Cancer Res; 2002 Mar; 62(5):1425-32. PubMed ID: 11888915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.
    Lengler J; Omann M; Düvier D; Holzmüller H; Gregor W; Salmons B; Günzburg WH; Renner M
    Biochem Pharmacol; 2006 Sep; 72(7):893-901. PubMed ID: 16887103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
    Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
    J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.